Cargando…

The Combination of Clindamycin and Gentamicin Is Adequate for Pelvic Inflammatory Disease: A Retrospective Cohort Study

Pelvic inflammatory disease (PID) affects 4.4% of women aged 18–44 in the United States, and may cause infertility if it is ineffectively treated. A combination of clindamycin and gentamicin is generally used for the treatment of PID. The benefit of adding metronidazole into the treatment combinatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Li-Yeh, Harnod, Tomor, Chang, Yu-Hsun, Chen, Hsuan, Ding, Dah-Ching
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469133/
https://www.ncbi.nlm.nih.gov/pubmed/34575253
http://dx.doi.org/10.3390/jcm10184145
_version_ 1784573852451340288
author Chen, Li-Yeh
Harnod, Tomor
Chang, Yu-Hsun
Chen, Hsuan
Ding, Dah-Ching
author_facet Chen, Li-Yeh
Harnod, Tomor
Chang, Yu-Hsun
Chen, Hsuan
Ding, Dah-Ching
author_sort Chen, Li-Yeh
collection PubMed
description Pelvic inflammatory disease (PID) affects 4.4% of women aged 18–44 in the United States, and may cause infertility if it is ineffectively treated. A combination of clindamycin and gentamicin is generally used for the treatment of PID. The benefit of adding metronidazole into the treatment combination still remains unclear, and this study was designed to evaluate its effectiveness. We retrospectively included 107 women who were diagnosed with PID from May 2013 to September 2020 in a single hospital. Based on their used antibiotic regimens, the patients were divided into three groups—those who were treated with clindamycin + gentamicin (group 1, n = 46), those who took regular antibiotics plus metronidazole (group 2, n = 27), and others (group 3, n = 34). Primary outcomes included the rates of taking surgery after failed antibiotics, occurrence/rupture of tubo-ovarian abscesses, and readmission within the following 6 months of first treatment. Secondary outcomes to assess were the length of stay (LOS) and expenditure for PID. There were no significant differences in the surgical rates, readmission rates, LOS and expenditure noted between the three groups. Subgroup analysis showed that visual analogue pain scores being 5 or more would increase the LOS by 3.83 days (p < 0.001), and body temperature > 38.3 °C or more would increase the treatment total expenditure (p < 0.001). Our study results suggest that the combination of clindamycin + gentamicin is a convincible treatment protocol for PID.
format Online
Article
Text
id pubmed-8469133
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84691332021-09-27 The Combination of Clindamycin and Gentamicin Is Adequate for Pelvic Inflammatory Disease: A Retrospective Cohort Study Chen, Li-Yeh Harnod, Tomor Chang, Yu-Hsun Chen, Hsuan Ding, Dah-Ching J Clin Med Article Pelvic inflammatory disease (PID) affects 4.4% of women aged 18–44 in the United States, and may cause infertility if it is ineffectively treated. A combination of clindamycin and gentamicin is generally used for the treatment of PID. The benefit of adding metronidazole into the treatment combination still remains unclear, and this study was designed to evaluate its effectiveness. We retrospectively included 107 women who were diagnosed with PID from May 2013 to September 2020 in a single hospital. Based on their used antibiotic regimens, the patients were divided into three groups—those who were treated with clindamycin + gentamicin (group 1, n = 46), those who took regular antibiotics plus metronidazole (group 2, n = 27), and others (group 3, n = 34). Primary outcomes included the rates of taking surgery after failed antibiotics, occurrence/rupture of tubo-ovarian abscesses, and readmission within the following 6 months of first treatment. Secondary outcomes to assess were the length of stay (LOS) and expenditure for PID. There were no significant differences in the surgical rates, readmission rates, LOS and expenditure noted between the three groups. Subgroup analysis showed that visual analogue pain scores being 5 or more would increase the LOS by 3.83 days (p < 0.001), and body temperature > 38.3 °C or more would increase the treatment total expenditure (p < 0.001). Our study results suggest that the combination of clindamycin + gentamicin is a convincible treatment protocol for PID. MDPI 2021-09-14 /pmc/articles/PMC8469133/ /pubmed/34575253 http://dx.doi.org/10.3390/jcm10184145 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chen, Li-Yeh
Harnod, Tomor
Chang, Yu-Hsun
Chen, Hsuan
Ding, Dah-Ching
The Combination of Clindamycin and Gentamicin Is Adequate for Pelvic Inflammatory Disease: A Retrospective Cohort Study
title The Combination of Clindamycin and Gentamicin Is Adequate for Pelvic Inflammatory Disease: A Retrospective Cohort Study
title_full The Combination of Clindamycin and Gentamicin Is Adequate for Pelvic Inflammatory Disease: A Retrospective Cohort Study
title_fullStr The Combination of Clindamycin and Gentamicin Is Adequate for Pelvic Inflammatory Disease: A Retrospective Cohort Study
title_full_unstemmed The Combination of Clindamycin and Gentamicin Is Adequate for Pelvic Inflammatory Disease: A Retrospective Cohort Study
title_short The Combination of Clindamycin and Gentamicin Is Adequate for Pelvic Inflammatory Disease: A Retrospective Cohort Study
title_sort combination of clindamycin and gentamicin is adequate for pelvic inflammatory disease: a retrospective cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469133/
https://www.ncbi.nlm.nih.gov/pubmed/34575253
http://dx.doi.org/10.3390/jcm10184145
work_keys_str_mv AT chenliyeh thecombinationofclindamycinandgentamicinisadequateforpelvicinflammatorydiseasearetrospectivecohortstudy
AT harnodtomor thecombinationofclindamycinandgentamicinisadequateforpelvicinflammatorydiseasearetrospectivecohortstudy
AT changyuhsun thecombinationofclindamycinandgentamicinisadequateforpelvicinflammatorydiseasearetrospectivecohortstudy
AT chenhsuan thecombinationofclindamycinandgentamicinisadequateforpelvicinflammatorydiseasearetrospectivecohortstudy
AT dingdahching thecombinationofclindamycinandgentamicinisadequateforpelvicinflammatorydiseasearetrospectivecohortstudy
AT chenliyeh combinationofclindamycinandgentamicinisadequateforpelvicinflammatorydiseasearetrospectivecohortstudy
AT harnodtomor combinationofclindamycinandgentamicinisadequateforpelvicinflammatorydiseasearetrospectivecohortstudy
AT changyuhsun combinationofclindamycinandgentamicinisadequateforpelvicinflammatorydiseasearetrospectivecohortstudy
AT chenhsuan combinationofclindamycinandgentamicinisadequateforpelvicinflammatorydiseasearetrospectivecohortstudy
AT dingdahching combinationofclindamycinandgentamicinisadequateforpelvicinflammatorydiseasearetrospectivecohortstudy